CHARLES SCHWAB INVESTMENT MANAGEMENT INC - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 180 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.

Quarter-by-quarter ownership
CHARLES SCHWAB INVESTMENT MANAGEMENT INC ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2024$11,032,128
+25.4%
1,785,134
+3.1%
0.00%0.0%
Q1 2024$8,797,559
-7.9%
1,731,803
+8.6%
0.00%0.0%
Q4 2023$9,550,672
-7.7%
1,594,436
+9.1%
0.00%
-33.3%
Q3 2023$10,342,514
+1.9%
1,460,807
+1.3%
0.00%0.0%
Q2 2023$10,147,491
-14.5%
1,441,405
+1.3%
0.00%
-25.0%
Q1 2023$11,868,821
-27.2%
1,423,120
+0.2%
0.00%
-20.0%
Q4 2022$16,306,043
-6.6%
1,420,387
+2.5%
0.01%
-16.7%
Q3 2022$17,466,000
+21.6%
1,386,148
+2.1%
0.01%
+20.0%
Q2 2022$14,358,000
-34.4%
1,357,003
+0.8%
0.01%
-28.6%
Q1 2022$21,900,000
+24.0%
1,346,841
+5.6%
0.01%
+40.0%
Q4 2021$17,657,000
-1.2%
1,274,815
+2.5%
0.01%
-16.7%
Q3 2021$17,879,000
-7.8%
1,244,166
+1.4%
0.01%0.0%
Q2 2021$19,401,000
+58.1%
1,227,111
+1.7%
0.01%
+50.0%
Q1 2021$12,275,000
+41.0%
1,206,966
+3.3%
0.00%
+33.3%
Q4 2020$8,707,000
+116.6%
1,168,691
-0.1%
0.00%
+50.0%
Q3 2020$4,020,000
-9.1%
1,170,046
+26.1%
0.00%0.0%
Q2 2020$4,422,000
+157.2%
927,944
+8.0%
0.00%
+100.0%
Q1 2020$1,719,000
-40.4%
859,007
+2.8%
0.00%
-50.0%
Q4 2019$2,882,000
+74.7%
835,249
+45.1%
0.00%
+100.0%
Q3 2019$1,650,000
-33.3%
575,806
-11.8%
0.00%
-50.0%
Q2 2019$2,474,000
-61.0%
652,733
-16.2%
0.00%
-50.0%
Q1 2019$6,345,000
+31.5%
779,365
+30.4%
0.00%0.0%
Q4 2018$4,825,000
+2.7%
597,822
-2.9%
0.00%
+33.3%
Q3 2018$4,700,000
+58.0%
615,903
+18.7%
0.00%
+50.0%
Q2 2018$2,975,000
+27.0%
519,060
+5.7%
0.00%0.0%
Q1 2018$2,342,000
-4.0%
490,976
-1.2%
0.00%0.0%
Q4 2017$2,440,000
+45.4%
496,792
+55.2%
0.00%
+100.0%
Q3 2017$1,678,000
-2.0%
320,078
+4.0%
0.00%
-50.0%
Q2 2017$1,712,000
-38.9%
307,811
-7.7%
0.00%
-33.3%
Q1 2017$2,801,000
+63.5%
333,373
+23.2%
0.00%
+50.0%
Q4 2016$1,713,000
+50.9%
270,581
+5.2%
0.00%
+100.0%
Q3 2016$1,135,000
+62.6%
257,183
+4.7%
0.00%0.0%
Q2 2016$698,000
+1.7%
245,729
+1.5%
0.00%0.0%
Q1 2016$686,000
-75.0%
242,201
-8.9%
0.00%
-75.0%
Q4 2015$2,745,000
-2.0%
265,970
+8.2%
0.00%0.0%
Q3 2015$2,802,000
-10.6%
245,760
+17.1%
0.00%0.0%
Q2 2015$3,134,000
+70.0%
209,875
+2.8%
0.00%
+33.3%
Q1 2015$1,844,000
-68.3%
204,106
-57.3%
0.00%
-66.7%
Q4 2014$5,818,000
+32.2%
478,383
+6.3%
0.01%
+28.6%
Q3 2014$4,402,000
+38.1%
450,021
+80.0%
0.01%
+40.0%
Q2 2014$3,187,000
+1159.7%
249,960
+945.9%
0.01%
Q1 2014$253,000
+39.0%
23,9000.0%0.00%
Q4 2013$182,0000.0%23,9000.0%0.00%
Q3 2013$182,000
+366.7%
23,9000.0%0.00%
Q2 2013$39,00023,9000.00%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q4 2020
NameSharesValueWeighting ↓
VHCP Management II, LLC 6,071,142$50,998,00020.86%
RTW INVESTMENTS, LP 3,458,120$29,048,0007.65%
ISZO CAPITAL MANAGEMENT LP 307,366$2,582,0004.49%
DAFNA Capital Management LLC 541,128$4,545,0003.84%
RA Capital Management 3,489,795$29,314,0003.60%
EMORY UNIVERSITY 375,348$3,153,0002.98%
Ghost Tree Capital, LLC 1,500,000$12,600,0002.35%
ACUTA CAPITAL PARTNERS, LLC 920,310$7,731,0001.83%
Avoro Capital Advisors LLC 1,603,001$13,465,0001.72%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 3,085,236$25,916,0001.00%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders